20 June 2019 - - US-based commercial-stage company Alcresta Therapeutics Inc has appointed Daniel Orlando as its chief executive officer and member of the board of directors, the company said.
Orlando joins Alcresta with more than 18 years of experience in executive roles leading organizations through rapid growth while successfully developing and launching therapeutics and biologics.
Prior to joining Alcresta, Daniel was chief operating officer at Vericel Corp., where during his tenure he led every function of the cell therapy company, most recently, the Commercial, Manufacturing, Engineering and R and D organisations.
Previously, Orlando held executive positions in Business Development, Marketing and Sales with Takeda as well as similar developmental roles at Abbott Laboratories.
Alcresta Therapeutics is focused on developing and commercialising novel, enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases.
Alcresta currently markets RELiZORB for enterally fed patients with pancreatic insufficiency, which occurs in cystic fibrosis, pancreatic cancer and pancreatitis, and is developing platform applications for patients with short bowel syndrome and prematurely born infants treated in the NICU.
Alcresta Therapeutics, Inc. is backed by top-tier investors: Athyrium Capital Management, Bessemer Venture Partners, HealthQuest Capital, Frazier Healthcare Partners, and Third Rock Ventures.